These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38773687)

  • 21. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
    Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
    Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.
    Westre B; Giske A; Guttormsen H; Wergeland Sørbye S; Skjeldestad FE
    PLoS One; 2019; 14(11):e0221546. PubMed ID: 31689301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result.
    Strang THR; Gottschlich A; Cook DA; Smith LW; Gondara L; Franco EL; van Niekerk DJ; Ogilvie GS; Krajden M
    Am J Obstet Gynecol; 2021 Nov; 225(5):511.e1-511.e7. PubMed ID: 34081897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
    Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
    J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.
    Isidean SD; Wang Y; Mayrand MH; Ratnam S; Coutlée F; Franco EL; Abrahamowicz M;
    Int J Cancer; 2019 May; 144(10):2408-2418. PubMed ID: 30411802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial.
    Gottschlich A; Gondara L; Smith LW; Cook D; Martin RE; Lee M; Peacock S; Proctor L; Stuart G; Krajden M; Franco EL; van Niekerk D; Ogilvie G
    Int J Cancer; 2022 Sep; 151(6):897-905. PubMed ID: 35460070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.
    Isidean SD; Mayrand MH; Ramanakumar AV; Gilbert L; Reid SL; Rodrigues I; Ferenczy A; Ratnam S; Coutlée F; Franco EL;
    Int J Cancer; 2016 Dec; 139(11):2456-66. PubMed ID: 27538188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study.
    Gottschlich A; Gondara L; Smith LW; Anderson JJ; Cook D; Krajden M; Lee M; Martin RE; Melnikow J; Peacock S; Proctor L; Stuart G; Franco EL; van Niekerk D; Ogilvie GS
    Lancet Reg Health Am; 2023 Oct; 26():100598. PubMed ID: 37786399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical Cancer Screening: A Review.
    Perkins RB; Wentzensen N; Guido RS; Schiffman M
    JAMA; 2023 Aug; 330(6):547-558. PubMed ID: 37552298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.
    Cuzick J; Szarewski A; Mesher D; Cadman L; Austin J; Perryman K; Ho L; Terry G; Sasieni P; Dina R; Soutter WP
    Int J Cancer; 2008 May; 122(10):2294-300. PubMed ID: 18240149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.